CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database


    • TOP

    UL56

    Mutations:

    Mutant Antiviral EC50 ratio Phenotype Assay Reference
    E2K Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V12L Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    C25F Letermovir 5.40 High level resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    V33A Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A36V Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    E75G Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L122P Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    R129H Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A221V Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    S229F Letermovir 1.80 No resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    S229Y Letermovir 2.00 Low level resistance Details Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    V231A Letermovir 2.10 Low level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    V231L Letermovir 5.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    V231L Letermovir 8.90 High level resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V231L Letermovir 8.10 High level resistance Details Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    N232Y Letermovir 17.00 High level resistance Details Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    Q234R Letermovir 2.00 Low level resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V236A Letermovir 2.90 Low level resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    V236L Letermovir 14.00 High level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    V236M Letermovir 45.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    V236M Maribavir 0.12 Possible hypersensitivity, no resistance Details Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. (Sep 2018)
    E237D Letermovir 10.00 High level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L241P Letermovir 218.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    D242G Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    L243P Letermovir 1.00 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    T244K Letermovir 3.30 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    L254F Letermovir 3.20 Intermediate level resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    L257F Letermovir 8.60 High level resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    L257I Letermovir 4.90 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    K258E Letermovir 14.00 High level resistance Details Comparison of Cytomegalovirus Terminase Gene Mutations Selected after Exposure to Three Distinct Inhibitor Compounds. (Nov 2017)
    F261C Letermovir 4.40 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    F261L Letermovir 2.80 Low level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    S262C Letermovir 1.00 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    Y321C Letermovir 4.60 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325F Letermovir 3000.00 High level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325R Letermovir 3000.00 High level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    C325Y Letermovir 8796.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    C325W Letermovir 9300.00 High level resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    A327V Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    L328I Letermovir 1.40 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    L328V Letermovir 1.90 No resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    M329I Letermovir 0.77 No resistance Details Phenotypes of cytomegalovirus genetic variants encountered in a letermovir clinical trial illustrate the importance of genotyping validation. (Aug 2024)
    M329T Letermovir 4.40 Intermediate level resistance Details Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. (Oct 2015)
    H335Y Letermovir 0.80 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    E339G Letermovir 1.20 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    F345L Letermovir 0.95-1.03 Range of values of No resistance Details Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection. (Nov 2022)
    K350R Letermovir 1.10 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    V363I Letermovir 3.70 Intermediate level resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    A365S Letermovir 2.00 Low level resistance Details New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir. (Sep 2018)
    N368I Letermovir 1.30 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    N368D Letermovir 2.00 Low level resistance Details A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. (Dec 2017)
    R369K Letermovir 4.90 Intermediate level resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    R369G Letermovir 44.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R369M Letermovir 13.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R369S Letermovir 48.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    R369T Letermovir 52.00 High level resistance Details Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients. (Mar 2020)
    E393K Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    R396S Letermovir 81.00 High level resistance Details Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. ( 2014)
    T399I Letermovir 0.80 No resistance Details Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing. (Nov 2022)
    A425V Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G436E Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    M442T Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A444G Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S445N Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    N446del Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    N446S Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    449-451del Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    450-453del Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    T452I Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S454N Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G460V Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A464V Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A464T Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V471A Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V476A Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    E485G Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    R507C Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    H509N Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    Q577R Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V582M Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    D586N Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A648R Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A648S Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G649D Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L658F Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    H698Q Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    C721Y Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    S749N Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V778A Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A779T Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A779V Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A788T Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    V793A Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    V793P Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    P800L Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    P803A Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    Y806T Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    T811P Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A812E Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    A812G Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    G813A Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    A820Q Natural polymorphism Details Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism. (Nov 2014)
    L831M Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    G840A Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)
    S848N Natural polymorphism Details Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity. ( 2008)

    Tilloy et al., 2024
    Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230